HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg
HCPCS Level II code J0013 designates esketamine nasal spray in a 1 mg unit of measure. As an FDA-approved formulation used in supervised outpatient settings, this drug-level code matters nationally for billing of medication supply and administration tied to mental health treatment pathways. Accurate coding affects claims processing, reimbursement, and clinical documentation for clinics and physician offices that provide supervised intranasal administration.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common billing contexts for outpatient administration, and clinical context for use of an esketamine nasal spray product. The publication highlights benchmarks for utilization and payment practices where available, summarizes recent policy updates affecting drug administration codes, and clarifies typical service lines and sites of service associated with this HCPCS Level II medication code.
The content is intended for revenue cycle leaders, billing staff, and clinical administrators seeking concise guidance on how HCPCS Level II code J0013 is used in practice and how payer policies can influence claims outcomes.
Sign up for hcpcs J0013 policy alerts
Get alerted when payer policies referencing J0013 are released or updated.
Billing Code Overview
HCPCS Level II code J0013 represents esketamine, nasal spray, 1 mg. This code denotes the medication product by dosage strength used for administration via a nasal spray formulation.
-
Service type: Drug administration via nasal spray
-
Typical site of service: Outpatient clinic or physician office where supervised administration of a nasal spray medication occurs
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with treatment-resistant major depressive disorder attends a specialized outpatient clinic for administration of intranasal esketamine. The patient has failed at least two adequate antidepressant trials and meets criteria for esketamine therapy. The multidisciplinary team includes a psychiatrist or certified prescriber, a registered nurse, and an observer. Prior to dosing, the patient undergoes baseline vital signs, a focused mental status exam, and confirmation of informed consent. The medication is prepared as J0013 (esketamine, nasal spray, 1 mg) in the clinic setting. The designated prescriber administers the required number of actuations per approved dosing protocol while the patient is seated. Monitoring for at least two hours post-dose includes repeated blood pressure and heart rate checks, assessment for sedation and dissociation, and evaluation for suicidal ideation. Adverse events such as transient hypertension or dissociation are managed per clinic protocol. The patient is discharged only when vital signs and mental status have returned to baseline and an escort is available if required by local policy or medication labeling. Typical site of service is an outpatient clinic or ambulatory infusion/medication administration center set up to meet REMS program requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JG | Drug or biological infused or injected at home under a DMEPOS benefit | Use when esketamine is administered at home under a qualifying durable medical equipment program (rare for this product). |
JW | Drug amount discarded/not administered to any patient | Use to report the amount of J0013 discarded after preparation when wastage occurs and bill only the administered portion. |
JZ | Indicates no drug was administered | Use when a dose of J0013 was prepared but not administered and documentation supports non-administration. |
GJ | Facility-based outpatient clinic services for drugs requiring observation | Use to indicate facility outpatient administration requiring monitoring (facility reporting where applicable). |
KE | Oral or topical controlled substance | Generally not applicable to J0013; listed for completeness when an administration requires special controlled-substance billing (rare). |
AA | Anesthesia services performed personally by the physician | Not typically used with J0013; included if anesthesia services are billed concurrently for unrelated procedures. |
QS | Monitored anesthesia care | Use only when monitored anesthesia care is provided concurrently and must be separately reported (uncommon for esketamine dosing). |
59 | Distinct procedural service | Use when another distinct service or procedure is performed on the same day and needs separate reporting from the drug administration. |
25 | Significant, separately identifiable E/M service by the same physician on the same day | Use if an evaluation and management service meets criteria in addition to J0013 administration. |
24 | Unrelated E/M service during postoperative period | Use if an unrelated E/M visit occurs during a global postoperative period on the same day as the drug administration. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207Q00000X | Psychiatry & Neurology | Psychiatrists who prescribe and oversee esketamine therapy in outpatient clinics. |
363LP0800X | Nurse Practitioner | Psychiatric or family nurse practitioners who administer or supervise therapy per state scope of practice. |
163W00000X | Emergency Medicine | Emergency physicians may manage acute adverse reactions or provide same-day dosing in certain systems. |
174400000X | Hospitalist | Hospital-based physicians involved when inpatient monitoring or consultation is required for complex cases. |
3336C0002X | Clinical Pharmacist | Pharmacists involved in medication preparation, dosing verification, and REMS compliance notes. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
F32.9 | Major depressive disorder, single episode, unspecified | Common indication for initiation of esketamine in treatment-resistant depression when a single current major depressive episode is documented. |
F33.9 | Major depressive disorder, recurrent, unspecified | Commonly used for patients with recurrent depressive episodes being considered for esketamine therapy. |
F33.1 | Major depressive disorder, recurrent severe without psychotic features | Used when severity justifies advanced therapies such as esketamine. |
F32.2 | Major depressive disorder, single episode, severe without psychotic features | Indicates severity that may prompt consideration of rapid-acting agents like esketamine. |
R45.851 | Suicidal ideation | Relevant because esketamine is used in acute settings for patients with suicidal ideation and requires close monitoring during administration. |
F43.21 | Adjustment disorder with depressed mood | Occasionally seen in clinical practice when depressive symptoms are significant and refractory to initial interventions; careful clinical correlation required. |
Z79.899 | Other long term (current) drug therapy | Used to indicate ongoing long-term pharmacologic therapy when documenting combination treatment with esketamine and oral antidepressants. |
Z13.89 | Encounter for screening for other specified diseases and disorders | Used when documenting pre-treatment screening evaluations relevant to esketamine initiation. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
99213 | Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes | Commonly billed when a focused E/M is performed the same day as J0013 administration to assess treatment response or manage side effects. |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Sometimes used in coding workflows for parenteral medication administration services; not a direct match for intranasal but listed when facilities use analogous administration codes for drug administration services. |
99214 | Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes | Used for more complex visits on the same day as dosing when a higher-level E/M service is provided. |
99406 | Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes | Example of adjunctive behavioral health services that may be provided during the treatment course (behavioral interventions commonly accompany therapy). |
96127 | Brief emotional/behavioral assessment with scoring and documentation per standardized instrument | Used when brief standardized symptom scoring (PHQ-9 or other scales) is performed before or after J0013 administration to document treatment response. |